Conflict of interest issues unseat medical journal editor

After failing to disclose conflicts of interest in more than 100 papers, one of the editors-in-chief and founders of Cancer Discovery will resign, according to a joint report from The New York Times and ProPublica.

José Baselga, MD, PhD, "resigned under pressure" Dec. 19 after the journal's publisher, the American Association for Cancer Research, found he did not meet standards for reporting conflicts of interest, according to the report. Dr. Baselga's resignation comes after a previous analysis by The New York Times and ProPublica found he failed to disclose financial ties to the drug industry and other healthcare companies in about 60 percent of his work published since 2013.

Dr. Baselga, a breast cancer research expert, will still be allowed to publish in the journal, as the AACR found his failure to disclose information was "inadvertent," according to the report.

Since the initial report broke, Dr. Baselga has resigned from his post as CMO of Memorial Sloan Kettering Cancer Center in New York City, resigned from the boards of Bristol-Myers Squibb and Varian Medical Systems, and corrected disclosures in the New England Journal of Medicine, Clinical Cancer Research, JAMA Oncology and Cancer Discovery.

Dr. Baselga edited Cancer Discovery for eight years and previously was president of AACR, according to the report.

Read the full story here.


More articles on leadership and management:

CMS probes potential conflicts of interest for accrediting groups
How Novant Health CEO Carl Armato's Type 1 diabetes changed the lives of more than 6,000 patients
Healthcare as a zero-sum game: 7 key points

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.


Featured Webinars

Featured Whitepapers